Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion

P. G. Montaldo, F. Figoli, M. L. Zanette, R. Sorio, M. Zucchetti, U. Tirelli, Maurizio D’Incalci

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The pharmacokinetics of etoposide (VP 16) and teniposide (VM 26) were studied after intrapleural administration to 3 patients with lung cancer and malignant pleural effusion. Comparison with the kinetic behavior of intravenously infused VP 16 and VM 26 in the same patients suggests that intrapleural drug delivery achieves higher and longer-lasting pleural concentrations, thus providing a theoretical basis for the palliative treatment of malignant pleural effusions. Although no systemic toxicity was observed after intrapleural administration of either drug, 1 of the 3 patients developed a transient asymptomatic hemorrhagic pleurisy during the first 2 days after the drug, alerting to the possible local toxicity of such treatment.

Original languageEnglish
Pages (from-to)55-61
Number of pages7
JournalOncology
Volume47
Issue number1
DOIs
Publication statusPublished - 1990

Fingerprint

Teniposide
Malignant Pleural Effusion
Etoposide
Pharmacokinetics
Pharmaceutical Preparations
Pleurisy
Palliative Care
Lung Neoplasms
Therapeutics

Keywords

  • Etoposide teniposide
  • Intracavitary chemotherapy
  • Lung cancer
  • Pharmacokinetics
  • Pleural effusion

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{2fb9c3d50be54fd9871441079c5106e1,
title = "Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion",
abstract = "The pharmacokinetics of etoposide (VP 16) and teniposide (VM 26) were studied after intrapleural administration to 3 patients with lung cancer and malignant pleural effusion. Comparison with the kinetic behavior of intravenously infused VP 16 and VM 26 in the same patients suggests that intrapleural drug delivery achieves higher and longer-lasting pleural concentrations, thus providing a theoretical basis for the palliative treatment of malignant pleural effusions. Although no systemic toxicity was observed after intrapleural administration of either drug, 1 of the 3 patients developed a transient asymptomatic hemorrhagic pleurisy during the first 2 days after the drug, alerting to the possible local toxicity of such treatment.",
keywords = "Etoposide teniposide, Intracavitary chemotherapy, Lung cancer, Pharmacokinetics, Pleural effusion",
author = "Montaldo, {P. G.} and F. Figoli and Zanette, {M. L.} and R. Sorio and M. Zucchetti and U. Tirelli and Maurizio D’Incalci",
year = "1990",
doi = "10.1159/000226785",
language = "English",
volume = "47",
pages = "55--61",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion

AU - Montaldo, P. G.

AU - Figoli, F.

AU - Zanette, M. L.

AU - Sorio, R.

AU - Zucchetti, M.

AU - Tirelli, U.

AU - D’Incalci, Maurizio

PY - 1990

Y1 - 1990

N2 - The pharmacokinetics of etoposide (VP 16) and teniposide (VM 26) were studied after intrapleural administration to 3 patients with lung cancer and malignant pleural effusion. Comparison with the kinetic behavior of intravenously infused VP 16 and VM 26 in the same patients suggests that intrapleural drug delivery achieves higher and longer-lasting pleural concentrations, thus providing a theoretical basis for the palliative treatment of malignant pleural effusions. Although no systemic toxicity was observed after intrapleural administration of either drug, 1 of the 3 patients developed a transient asymptomatic hemorrhagic pleurisy during the first 2 days after the drug, alerting to the possible local toxicity of such treatment.

AB - The pharmacokinetics of etoposide (VP 16) and teniposide (VM 26) were studied after intrapleural administration to 3 patients with lung cancer and malignant pleural effusion. Comparison with the kinetic behavior of intravenously infused VP 16 and VM 26 in the same patients suggests that intrapleural drug delivery achieves higher and longer-lasting pleural concentrations, thus providing a theoretical basis for the palliative treatment of malignant pleural effusions. Although no systemic toxicity was observed after intrapleural administration of either drug, 1 of the 3 patients developed a transient asymptomatic hemorrhagic pleurisy during the first 2 days after the drug, alerting to the possible local toxicity of such treatment.

KW - Etoposide teniposide

KW - Intracavitary chemotherapy

KW - Lung cancer

KW - Pharmacokinetics

KW - Pleural effusion

UR - http://www.scopus.com/inward/record.url?scp=0025122166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025122166&partnerID=8YFLogxK

U2 - 10.1159/000226785

DO - 10.1159/000226785

M3 - Article

C2 - 2300386

AN - SCOPUS:0025122166

VL - 47

SP - 55

EP - 61

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -